Dermatologie5 articles

Impact 3

Sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis.

Publié: 2026-12-01

The Journal of dermatological treatment

MediLens Indexé: 2026-05-23

This study evaluated the off-treatment disease control in patients with moderate-to-severe atopic dermatitis (AD) following 12 weeks of abrocitinib 200 mg. In the phase 3 JADE REGIMEN study, patients who achieved significant improvement were randomized to receive either placebo or continued treat...

Lire sur PubMed

Impact 2

Efficacy and safety of recombinant human epidermal growth factor combined with fractional carbon dioxide laser for facial atrophic acne scars: a systematic review and meta-analysis of randomized trials.

Publié: 2026-05-22

Lasers in medical science

MediLens Indexé: 2026-05-23

This systematic review assessed the efficacy and safety of recombinant human epidermal growth factor (rhEGF) combined with fractional CO₂ laser therapy for atrophic acne scars. Twelve randomized controlled trials involving 1,044 patients were analyzed, showing significant reductions in ECCA and V...

Lire sur PubMed

Impact 2

Research on multi-stage deep learning based intelligent diagnosis of skin diseases and skin medicine diagnosis community construction concept.

Publié: 2026-05-22

Scientific reports

MediLens Indexé: 2026-05-23

This study introduces a multi-stage intelligent diagnosis framework utilizing deep learning to enhance dermatological decision-making. The framework employs a LeNet-5 convolutional neural network for initial classification of skin diseases and further assesses disease severity and progression. By...

Lire sur PubMed

Impact 1

Pregnancy and risk of melanoma: a matched retrospective cohort study.

Publié: 2026-05-22

Melanoma research

MediLens Indexé: 2026-05-23

This study investigates the relationship between pregnancy and melanoma risk using a large retrospective cohort. It found no significant increase in the risk of invasive melanoma or melanoma in situ during pregnancy compared to nonpregnant women of reproductive age. The findings suggest that preg...

Lire sur PubMed

Impact 3

Catestatin peptide impedes melanoma progression and drug resistance by reprogramming oncogenic signaling pathways.

Publié: 2026-05-21

Oncogenesis

MediLens Indexé: 2026-05-23

This study investigates catestatin (CST), a peptide derived from Chromogranin A, as a potential therapeutic agent for melanoma. It demonstrates that CST expression decreases with disease progression, suggesting a tumor-suppressive role. Restoration of CST in melanoma cells led to apoptosis and re...

Lire sur PubMed

Tendances de la Recherche Médicale

Dermatologie5 articles

Sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis.

Efficacy and safety of recombinant human epidermal growth factor combined with fractional carbon dioxide laser for facial atrophic acne scars: a systematic review and meta-analysis of randomized trials.

Research on multi-stage deep learning based intelligent diagnosis of skin diseases and skin medicine diagnosis community construction concept.

Pregnancy and risk of melanoma: a matched retrospective cohort study.

Catestatin peptide impedes melanoma progression and drug resistance by reprogramming oncogenic signaling pathways.

Recevez des résumés quotidiens personnalisés